MoonLake Immunotherapeutics

Healthcare · Biotechnology · Switzerland

Last price 11.78 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.00B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.